These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11763327)

  • 1. Vaccines based on recombinant antigen strategies.
    Minor P
    Dev Biol (Basel); 2001; 105():189-94. PubMed ID: 11763327
    [No Abstract]   [Full Text] [Related]  

  • 2. Inactivated vaccines based on alternatives to wild-type seed virus.
    Chumakov K; Dragunsky E; Ivshina A; Enterline J; Wells V; Nomura T; Gromeier M; Wimmer E
    Dev Biol (Basel); 2001; 105():171-7. PubMed ID: 11763325
    [No Abstract]   [Full Text] [Related]  

  • 3. Antigenic hybrids of poliovirus.
    Hogle JM
    Nature; 1988 Mar; 332(6159):13-4. PubMed ID: 2831454
    [No Abstract]   [Full Text] [Related]  

  • 4. Antigen chimaeras of poliovirus as potential new vaccines.
    Burke KL; Dunn G; Ferguson M; Minor PD; Almond JW
    Nature; 1988 Mar; 332(6159):81-2. PubMed ID: 2450279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular biology of poliovaccines.
    Minor PD
    J Gen Virol; 1992 Dec; 73 ( Pt 12)():3065-77. PubMed ID: 1335021
    [No Abstract]   [Full Text] [Related]  

  • 6. [Variability of poliomyelitis virus strains in nature and significance of this factor for the prevention of poliomyelitis].
    Gendon IuZ
    Vopr Virusol; 1988; 33(2):137-41. PubMed ID: 2457986
    [No Abstract]   [Full Text] [Related]  

  • 7. Mapping of type 1 poliovirus neutralization epitopes.
    Blondel B; Crainic R; Dufraisse G; Candréa A; Horaud F
    Dev Biol Stand; 1985; 60():337-42. PubMed ID: 2412917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, construction, and characterization of poliovirus antigen chimeras.
    Evans DJ; Almond JW
    Methods Enzymol; 1991; 203():386-400. PubMed ID: 1662331
    [No Abstract]   [Full Text] [Related]  

  • 9. Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains.
    Sawyer LA; McInnis J; Albrecht P
    Biologicals; 1993 Jun; 21(2):169-77. PubMed ID: 8297601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manipulation of the cellular binding properties of poliovirus: implications for non-target effects of recombinant vaccines.
    Whelan SP; Evans D; Almond JW
    Dev Biol Stand; 1995; 84():129-36. PubMed ID: 7796945
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073.
    Kouiavskaia DV; Dragunsky EM; Liu HM; Oberste MS; Collett MS; Chumakov KM
    Antivir Ther; 2011; 16(7):999-1004. PubMed ID: 22024515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete genomic characterization of an intertypic Sabin 3/Sabin 2 capsid recombinant.
    Dedepsidis E; Pliaka V; Kyriakopoulou Z; Brakoulias C; Levidiotou-Stefanou S; Pratti A; Mamuris Z; Markoulatos P
    FEMS Immunol Med Microbiol; 2008 Apr; 52(3):343-51. PubMed ID: 18328076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poliovirus vaccines.
    Racaniello VR
    Biotechnology; 1992; 20():205-22. PubMed ID: 1318134
    [No Abstract]   [Full Text] [Related]  

  • 14. When can we stop using oral poliovirus vaccine?
    Hull HF; Minor PD
    J Infect Dis; 2005 Dec; 192(12):2033-5. PubMed ID: 16288363
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: world wide experience with inactivated poliovirus vaccine.
    Arya SC; Agarwal N
    Vaccine; 2009 Jan; 27(1):1. PubMed ID: 18952133
    [No Abstract]   [Full Text] [Related]  

  • 16. Antigenic sites on type 2 poliovirus.
    Patel V; Ferguson M; Minor PD
    Virology; 1993 Jan; 192(1):361-4. PubMed ID: 7685967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenic, non-infectious polio subviral particles synthesized in Saccharomyces cerevisiae.
    Rombaut B; Jore JP
    J Gen Virol; 1997 Aug; 78 ( Pt 8)():1829-32. PubMed ID: 9266976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preexisting immunity to poliovirus does not impair the efficacy of recombinant poliovirus vaccine vectors.
    Mandl S; Hix L; Andino R
    J Virol; 2001 Jan; 75(2):622-7. PubMed ID: 11134275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antigenicity determination of inactivated poliovirus--the micro-neutralization inhibition test].
    Jiang SD; Pye D
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1985 Aug; 7(4):309-12. PubMed ID: 3011295
    [No Abstract]   [Full Text] [Related]  

  • 20. Engineering poliovirus as a vaccine vector for the expression of diverse antigens.
    Andino R; Silvera D; Suggett SD; Achacoso PL; Miller CJ; Baltimore D; Feinberg MB
    Science; 1994 Sep; 265(5177):1448-51. PubMed ID: 8073288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.